Cargando…
Barriers to medical device innovation
The US Food and Drug Administration (FDA) has defined a medical device as a health care product that does not achieve it’s purpose by chemical action or by being metabolized. This means that a vast number of products are considered medical devices. Such devices play an essential role in the practice...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063798/ https://www.ncbi.nlm.nih.gov/pubmed/24966699 http://dx.doi.org/10.2147/MDER.S43369 |
_version_ | 1782321861630099456 |
---|---|
author | Bergsland, Jacob Elle, Ole Jakob Fosse, Erik |
author_facet | Bergsland, Jacob Elle, Ole Jakob Fosse, Erik |
author_sort | Bergsland, Jacob |
collection | PubMed |
description | The US Food and Drug Administration (FDA) has defined a medical device as a health care product that does not achieve it’s purpose by chemical action or by being metabolized. This means that a vast number of products are considered medical devices. Such devices play an essential role in the practice of medicine. The FDA classifies medical devices in three classes, depending on the risk of the device. Since Class I and II devices have relatively simple requirements for getting to the market, this review will focus on “implantable devices”, which, in general, belong to Class III. The European Union and Canada use a slightly different classification system. While early generations of medical devices were introduced without much testing, either technical or clinical, the process of introducing a Class III medical device from concept to clinical practice has become strongly regulated and requires extensive technological and clinical testing. The modern era of implantable medical devices may be considered to have started in the 1920s with development of artificial hips. The implantable pacemaker was another milestone and pacemakers and cardioverters/defibrillators have since saved millions of lives and created commercial giants in the medical device industry. This review will include some examples of cardiovascular devices. Similar considerations apply to the total implantable device market, although clinical and technological applications obviously vary considerably. |
format | Online Article Text |
id | pubmed-4063798 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-40637982014-06-25 Barriers to medical device innovation Bergsland, Jacob Elle, Ole Jakob Fosse, Erik Med Devices (Auckl) Review The US Food and Drug Administration (FDA) has defined a medical device as a health care product that does not achieve it’s purpose by chemical action or by being metabolized. This means that a vast number of products are considered medical devices. Such devices play an essential role in the practice of medicine. The FDA classifies medical devices in three classes, depending on the risk of the device. Since Class I and II devices have relatively simple requirements for getting to the market, this review will focus on “implantable devices”, which, in general, belong to Class III. The European Union and Canada use a slightly different classification system. While early generations of medical devices were introduced without much testing, either technical or clinical, the process of introducing a Class III medical device from concept to clinical practice has become strongly regulated and requires extensive technological and clinical testing. The modern era of implantable medical devices may be considered to have started in the 1920s with development of artificial hips. The implantable pacemaker was another milestone and pacemakers and cardioverters/defibrillators have since saved millions of lives and created commercial giants in the medical device industry. This review will include some examples of cardiovascular devices. Similar considerations apply to the total implantable device market, although clinical and technological applications obviously vary considerably. Dove Medical Press 2014-06-13 /pmc/articles/PMC4063798/ /pubmed/24966699 http://dx.doi.org/10.2147/MDER.S43369 Text en © 2014 Bergsland et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Bergsland, Jacob Elle, Ole Jakob Fosse, Erik Barriers to medical device innovation |
title | Barriers to medical device innovation |
title_full | Barriers to medical device innovation |
title_fullStr | Barriers to medical device innovation |
title_full_unstemmed | Barriers to medical device innovation |
title_short | Barriers to medical device innovation |
title_sort | barriers to medical device innovation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063798/ https://www.ncbi.nlm.nih.gov/pubmed/24966699 http://dx.doi.org/10.2147/MDER.S43369 |
work_keys_str_mv | AT bergslandjacob barrierstomedicaldeviceinnovation AT elleolejakob barrierstomedicaldeviceinnovation AT fosseerik barrierstomedicaldeviceinnovation |